Last updated 13 days ago

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

1280 patients around the world

Available in Puerto Rico, Guatemala, United States, Mexico

AbbVie

2Research sites

1280Patients around the world

This study is for people with

Hidradenitis suppurativa

From 12 Years

All Gender

: Diagnosis of moderate to severe HS for at least 6 months prior to Baseline as determined by the investigator.
Total abscess and inflammatory nodule count of ≥ 5 at Baseline.
Hidradenitis suppurativa lesions present in at least two distinct anatomic areas at Baseline.
At least 1 anatomic area of HS involvement characterized as Hurley Stage II or higher at Baseline.

: Any evidence of Hepatitis B virus or hepatitis C virus infection.
Confirmed positive anti-HIV antibody test.
Evidence of active tuberculosis or meets tuberculosis exclusionary parameter.

Dermos

Recruiting

Zone 15, Guatemala City, Guatemala

Eukarya PharmaSite

Recruiting

De La Clínica 2520, Sertoma, 64718 Monterrey, N.L.

StudyIntrepid

SponsorAbbVie

Study typeInterventional

Conditions

Hidradenitis suppurativa

Requirements

From 12 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT06468228